November 21, 2016
Salk Institute finding could lead to treatment designs for immune-based cancer and autoimmune disease
Salk Institute finding could lead to treatment designs for immune-based cancer and autoimmune disease

点击此处 用于高分辨率图像。.
版权:萨克研究所
LA JOLLA—When a receptor on the surface of a T cell—a sentry of the human immune system—senses a single particle from a harmful intruder, it immediately kicks the cell into action, launching a larger immune response. But exactly how the signal from a single receptor, among thousands on each T cell, can be amplified to affect a whole cell has puzzled immunologists for decades.
Now, Salk scientists have discovered the key to the amplification of an “invader” signal. The T cell receptor that detects the intruder turns into a mini-machine, activating and releasing copy after copy of a protein called ZAP70. The finding, published in Nature Immunology on November 21, 2016, could help scientists design better immune-mediated treatments for 癌症 or autoimmune diseases.
“This is really the first amplification method that’s been found at this level of the immune response,” says senior author Björn Lillemeier, an associate professor in Salk’s Nomis Foundation Laboratories for Immunobiology and Microbial Pathogenesis and the Waitt Advanced Biophotonics Center. “It answers a longstanding question that has bugged immunologists for more than three decades.”
T cells are central in the adaptive immune response, which is the body’s ability to recognize pathogens and respond to them. A single T cell’s receptors screen thousands of molecules at any given second, but most of them originate from the body’s own proteins and have to be ignored as “self.” Researchers have struggled to explain how, in the wake of overwhelming “self” signals, a T cell can detect and respond to one or two “invader” signals.
Lillemeier’s lab studied ZAP70, a protein that associates with T cell receptors and becomes activated when the receptors recognize a foreign molecule. To track the activity and location of ZAP70 molecules, the team tagged them with a fluorescent marker while anchoring each T cell receptor in place. To the group’s surprise, ZAP70 molecules were being activated by the T cell receptors and then moving away, spreading throughout the cell.
“This is a completely different method of amplification than we expected,” says Zachary Katz, a research associate in the Lillemeier lab and first author of the new work. “Everyone always thought the amplification would be determined by the interaction between the foreign molecule and the T cell receptor, but this is happening downstream of the receptor.”

点击此处 for a high resolution image
版权:萨克研究所
By churning out ZAP70 and sending it throughout the cell—as opposed to just activating a handful of ZAP70s and keeping them tethered to the T cell receptor—the immune cells can rapidly spread a signal throughout the cell.
“What we saw is that at the beginning of signaling, you have lots of ZAP70 being released from the T cell receptor to amplify and distribute the signal,” says Lillemeier. “But once the signaling is established, the T cell receptor actually adapts and stops releasing so much of ZAP70.”
Questions remain on how the process works, including what the ultimate destinations of the ZAP70 molecules are and how they go on to transmit signals. But the observation, Lillemeier says, is progress toward understanding how T cells identify and react to pathogens.
“It’s really important to understand this process since T cells are at the center of the adaptive immune response,” he says. “If the receptors are not controlled well, you’re sick; you might either have an autoimmune disease or you can’t respond to infections.” Being able to make the receptors have a stronger or weaker signal—perhaps by changing how much ZAP70 they activate and release—could help treat these kinds of diseases, he adds.
Other researchers on the study were Lucie Novotná and Amy Blount of the Salk Institute.
这项工作以及参与研究的学者得到了以下机构资助: Nomis Foundation, , 那个 Waitt Foundation and the James B. Pendleton Charitable Trust, the 美国国立卫生研究院, a Pioneer Fund Postdoctoral Scholar Award, the Salk Institute Cancer Center core facilities funded by the 国家癌症研究所 and the Mass Spectrometry Core of the Salk Institute supported by the 赫尔姆斯利基因组医学中心.
日记
Nature Immunology
作者
Zachary B Katz, Lucie Novotná, Amy Blount, Björn F Lillemeier
宣传办公室
电话:(858) 453-4100
press@salk.edu
萨尔克研究所是一个独立的非营利性研究机构,由首个安全有效的脊髓灰质炎疫苗的研发者乔纳斯·索尔克于1960年创立。该研究所的使命是推动以合作、敢于冒险为特点的基础性研究,以应对癌症、阿尔茨海默病和农业脆弱性等社会最紧迫的挑战。这项基础科学支撑着所有的转化研究,产生有助于全球新药和创新的见解。.